These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 5102483)
1. [C-283 in treatment of peritoneal and pleural effusions in patients with ovarian carcinoma]. Kwaśniewska-Rokicińska Pol Tyg Lek; 1971 Mar; 26(10):361-3. PubMed ID: 5102483 [No Abstract] [Full Text] [Related]
2. [C-283 in the treatment of pleural and peritoneal effusions in cases of ovarian cancer]. Kwaśniewska-Rokicińska ; Swiecki J Pol Tyg Lek; 1971 Aug; 26(33):1288-90. PubMed ID: 5093971 [No Abstract] [Full Text] [Related]
3. Biochemical blood studies in patients with ovarian carcinoma treated with C-283. 3. Immunoelectrophoresis of serum proteins. Dobryszycka W; Gerber J; Jabloński K; Bec I Arch Immunol Ther Exp (Warsz); 1972; 20(3):367-73. PubMed ID: 4115628 [No Abstract] [Full Text] [Related]
4. The influence of aminoacridine derivative (C-283) on the ultrastructural pattern of human carcinoma cells. Vorbrodt A; Krzyzowska-Gruca S; Gruca S; Kwaśniewska-Rokicińska C Ann Med Sect Pol Acad Sci; 1974; 19(2):153-4. PubMed ID: 4454745 [No Abstract] [Full Text] [Related]
5. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters. Stathopoulos GP; Baxevanis CN; Papadopoulos NG; Zarkadis IK; Papacostas P; Michailakis E; Tsiatas ML; Papamichail M Anticancer Res; 1996; 16(6B):3855-60. PubMed ID: 9042270 [TBL] [Abstract][Full Text] [Related]
6. [Results of ledakrin treatment of patients with neoplastic effusions]. Kwaśniewska-Rokicińska C; Zielonkowa I; Dedyk-Drosik B; Drosik K Nowotwory; 1979; 29(4):303-6. PubMed ID: 395508 [No Abstract] [Full Text] [Related]
7. Behavior of some biochemical components of blood of patients with ovarian carcinoma during Ledakrin treatment. Dobryszcka W Mater Med Pol; 1976; 8(3):302-10. PubMed ID: 1034859 [No Abstract] [Full Text] [Related]
8. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions. Perez-Soler R; Shin DM; Siddik ZH; Murphy WK; Huber M; Lee SJ; Khokhar AR; Hong WK Clin Cancer Res; 1997 Mar; 3(3):373-9. PubMed ID: 9815694 [TBL] [Abstract][Full Text] [Related]
9. Biochemical studies of cancer patients treated with acridine derivative (C-283). IV. Changes in the levels of serum haptoglobin and sialic acid. Dobryszycka W; Osada J; Gerber J; Jablonski K Arch Immunol Ther Exp (Warsz); 1973; 21(2):271-9. PubMed ID: 4790848 [No Abstract] [Full Text] [Related]
10. Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study. Plaxe SC; Blessing JA; Bookman MA; Creasman WT Gynecol Oncol; 2002 Jan; 84(1):32-5. PubMed ID: 11748972 [TBL] [Abstract][Full Text] [Related]
11. [Methyl-GAG, an effective cytotoxic drug for treatment of neoplastic exsudates (author's transl)]. Tanneberger S; Matthias M; Rieche K Arch Geschwulstforsch; 1974; 43(1):68-74. PubMed ID: 4849186 [No Abstract] [Full Text] [Related]
12. Expression of the peroxisome proliferator-activated receptors-alpha, -beta, and -gamma in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival. Davidson B; Hadar R; Stavnes HT; Trope' CG; Reich R Hum Pathol; 2009 May; 40(5):705-13. PubMed ID: 19157507 [TBL] [Abstract][Full Text] [Related]
13. Nuclear and nucleolar ultrastructural lesions induced by 1-nitro-9-aminoacridine (C-283) in human ovarian carcinoma cells. Krzyzowska-Gruca S; Gruca S; Kwaśniewska-Rokicińska C; Vorbrodt A Eur J Cancer (1965); 1973; 9(11-12):785-8. PubMed ID: 4804305 [No Abstract] [Full Text] [Related]
14. [Preliminary evaluation of the toxicity of C-283 compound used intravenously]. Kwaśniewska-Rokicińska ; Swiecki J Pol Tyg Lek; 1971 Jul; 26(28):1086-8. PubMed ID: 5096683 [No Abstract] [Full Text] [Related]
15. [Radioactive gold treatment of effusions caused by neoplasms]. Rotte K; Feltmann K Med Klin; 1969 Sep; 64(36):1598-603. PubMed ID: 4310135 [No Abstract] [Full Text] [Related]
16. [Paraneoplastic superior vena cava thrombosis disclosing an ovarian tumor]. Padovani M; Tillie-Leblond I; Vennin P; Demarcq G; Wallaert B Rev Mal Respir; 1996 Dec; 13(6):598-600. PubMed ID: 9036506 [TBL] [Abstract][Full Text] [Related]
17. [Lymphocytosis in malignant effusions]. Hruczkowska E Pol Tyg Lek; 1969 Dec; 24(49):1895-6. PubMed ID: 5369043 [No Abstract] [Full Text] [Related]
18. The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma. Eitan R; Levine DA; Abu-Rustum N; Sonoda Y; Huh JN; Franklin CC; Stevens TA; Barakat RR; Chi DS Cancer; 2005 Apr; 103(7):1397-401. PubMed ID: 15726548 [TBL] [Abstract][Full Text] [Related]
19. HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. Davidson B; Elstrand MB; McMaster MT; Berner A; Kurman RJ; Risberg B; Trope CG; Shih IeM Gynecol Oncol; 2005 Jan; 96(1):42-7. PubMed ID: 15589578 [TBL] [Abstract][Full Text] [Related]